Prediction of Cardiovascular Disease Risk by Cardiac Biomarkers in 2 United Kingdom Cohort Studies: Does Utility Depend on Risk Thresholds for Treatment?

Hypertension

Volumn 67, Issue 2, 2016, Pages 309-315

  Welsh, Paul ^a   Hart, Carole ^b   Papacosta, Olia ^c   Preiss, David ^a   McConnachie, Alex ^b   Murray, Heather ^b   Ramsay, Sheena ^c   Upton, Mark ^d   Watt, Graham ^c   Whincup, Peter ^c   Wannamethee, Goya ^b   Sattar, Naveed ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d Helmsley Medical Centre   (United Kingdom)

Author keywords

Adrenomedullin; biomarkers; cardiovascular diseases; natriuretic peptides; risk factors; troponin T

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; PROADRENOMEDULLIN; TROPONIN T; BIOLOGICAL MARKER;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL DECISION MAKING; COHORT ANALYSIS; FAMILY STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; UNITED KINGDOM; ADULT; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; DISEASE MANAGEMENT; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT;

ADULT; AGED; BIOMARKERS; CARDIOVASCULAR DISEASES; DISEASE MANAGEMENT; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; UNITED KINGDOM;

EID: 84954348360     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.115.06501     Document Type: Article

References (23)

1. Yu T, Vollenweider D, Varadhan R, Li T, Boyd C, Puhan MA. Support of personalized medicine through risk-stratified treatment recommendations-an environmental scan of clinical practice guidelines. BMC Med. 2013;11:7. doi: 10.1186/1741-7015-11-7.
2. Hippisley-Cox J, Coupland C, Robson J, Brindle P. Derivation, validation, and evaluation of a new QRISK model to estimate lifetime risk of cardiovascular disease: cohort study using QResearch database. BMJ. 2010;341:c6624.
3. Perk J, De Backer G, Gohlke H, et al; Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice; European Association for Cardiovascular Prevention and Rehabilitation. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Atherosclerosis. 2012;223:1-68. doi: 10.1016/j.atherosclerosis.2012.05.007.
4. Woodward M, Brindle P, Tunstall-Pedoe H; SIGN Group on Risk Estimation. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart. 2007;93:172-176. doi: 10.1136/hrt.2006.108167.
5. Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 pt B):2889-2934. doi: 10.1016/j.jacc.2013.11.002.
6. National Institute for Health and Care Excellence. Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease. 2014. http://www.nice.org.uk/guidance/cg181/chapter/1-recommendations. Accessed November 11, 2015.
7. Welsh P, Doolin O, Willeit P, Packard C, Macfarlane P, Cobbe S, Gudnason V, Di Angelantonio E, Ford I, Sattar N. N-terminal pro-B-type natriuretic peptide and the prediction of primary cardiovascular events: results from 15-year follow-up of WOSCOPS. Eur Heart J. 2013;34:443-450. doi: 10.1093/eurheartj/ehs239.
8. Wannamethee SG, Welsh P, Lowe GD, Gudnason V, Di Angelantonio E, Lennon L, Rumley A, Whincup PH, Sattar N. N-terminal pro-brain natriuretic Peptide is a more useful predictor of cardiovascular disease risk than C-reactive protein in older men with and without pre-existing cardiovascular disease. J Am Coll Cardiol. 2011;58:56-64. doi: 10.1016/j.jacc.2011.02.041.
9. Zeller T, Tunstall-Pedoe H, Saarela O, Ojeda F, Schnabel RB, Tuovinen T, Woodward M, Struthers A, Hughes M, Kee F, Salomaa V, Kuulasmaa K, Blankenberg S; MORGAM Investigators. High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort. Eur Heart J. 2014;35:271-281. doi: 10.1093/eurheartj/eht406.
10. Hillis GS, Welsh P, Chalmers J, Perkovic V, Chow CK, Li Q, Jun M, Neal B, Zoungas S, Poulter N, Mancia G, Williams B, Sattar N, Woodward M. The relative and combined ability of high-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide to predict cardiovascular events and death in patients with type 2 diabetes. Diabetes Care. 2014;37:295-303. doi: 10.2337/dc13-1165.
11. Melloni C, Roe MT. Cardiac troponin and risk stratification in ischemic heart disease. N Engl J Med. 2015;373:672-674. doi: 10.1056/NEJMe1506298.
12. Sabatine MS, Morrow DA, de Lemos JA, Omland T, Sloan S, Jarolim P, Solomon SD, Pfeffer MA, Braunwald E. Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease. Circulation. 2012;125:233-240. doi: 10.1161/CIRCULATIONAHA.111.063842.
13. Schnabel RB, Schulz A, Messow CM, et al. Multiple marker approach to risk stratification in patients with stable coronary artery disease. Eur Heart J. 2010;31:3024-3031. doi: 10.1093/eurheartj/ehq322.
14. Melander O, Newton-Cheh C, Almgren P, Hedblad B, Berglund G, Engström G, Persson M, Smith JG, Magnusson M, Christensson A, Struck J, Morgenthaler NG, Bergmann A, Pencina MJ, Wang TJ. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA. 2009;302:49-57. doi: 10.1001/jama.2009.943.
15. Brindle PM, McConnachie A, Upton MN, Hart CL, Davey Smith G, Watt GC. The accuracy of the Framingham risk-score in different socioeconomic groups: a prospective study. Br J Gen Pract. 2005;55:838-845.
16. Shaper AG, Pocock SJ, Walker M, Cohen NM, Wale CJ, Thomson AG. British Regional Heart Study: cardiovascular risk factors in middle-aged men in 24 towns. BMJ. (Clin Res Ed). 1981;283:179-186.
17. Upton MN, McConnachie A, McSharry C, Hart CL, Smith GD, Gillis CR, Watt GC. Intergenerational 20 year trends in the prevalence of asthma and hay fever in adults: the Midspan family study surveys of parents and offspring. BMJ. 2000;321:88-92.
18. Welsh P, Doolin O, McConnachie A, Boulton E, McNeil G, Macdonald H, Hardcastle A, Hart C, Upton M, Watt G, Sattar N. Circulating 25OHD, dietary vitamin D, PTH, and calcium associations with incident cardiovascular disease and mortality: the MIDSPAN Family Study. J Clin Endocrinol Metab. 2012;97:4578-4587. doi: 10.1210/jc.2012-2272.
19. Newson RB. Comparing the predictive powers of survival models using Harrell's C or Somers' D. Stata J. 2010;10:339-358.
20. Uno H, Tian L, Cai T, Kohane IS, Wei LJ. A unified inference procedure for a class of measures to assess improvement in risk prediction systems with survival data. Stat Med. 2013;32:2430-2442. doi: 10.1002/sim.5647.
21. Pfister R, Sharp S, Luben R, Welsh P, Barroso I, Salomaa V, Meirhaeghe A, Khaw KT, Sattar N, Langenberg C, Wareham NJ. Mendelian randomization study of B-type natriuretic peptide and type 2 diabetes: evidence of causal association from population studies. PLoS Med. 2011;8:e1001112. doi: 10.1371/journal.pmed.1001112.
22. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004. doi: 10.1056/NEJMoa1409077.
23. Daniels LB, Clopton P, deFilippi CR, Sanchez O, Bahrami H, Lima JAC, Tracy RP, Siscovick D, Bertoni AG, Greenland P, Cushman M, Maisel AS, Criqui MH. Serial measurement of N-terminal pro-B-type natriuretic peptide and cardiac troponin T for cardiovascular disease risk assessment in the Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J. 2015;170:1170-1183.